Frederick Briccetti - Concepedia

Author

Frederick Briccetti

Dana-Farber Cancer Institute ORCID

Also Known As

Carey, Lisa A., Frederick Briccetti, Frederick M. Briccetti, Meredith Faggen

Publications

778

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute University of North Carolina at Chapel Hill University of Chicago Harvard University Cornell University

About

Frederick Briccetti is an author at Dana-Farber Cancer Institute specializing in medicine, cancer therapeutics, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	293
2	Immunology	2	2	245
3	Health Sciences	1	1	26
4	Natural Sciences	1	1	219
5	Cell Biology	1	1	219

Frederick Briccetti

Publications

627

Citations

H-Index

Page 1

	Year	Citations
Analysis of CD36 Binding Domains: Ligand Specificity Controlled by Dephosphorylation of an Ectodomain Adam S. Asch, Isaac Liu, Frederick Briccetti, Science ImmunologyMolecular BiologyPlatelet ReactivityImmune SystemCd36 Binding	1993	219
Thalidomide and rituximab in Waldenstrom macroglobulinemia Steven P. Treon, Jacob D. Soumerai, Andrew R. Branagan, Blood	2008	143
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial Sara M. Tolaney, Nabihah Tayob, Chau T. Dang, Journal of Clinical Oncology	2021	131
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial) Kathryn J. Ruddy, Yue Zheng, Nabihah Tayob, Breast Cancer Research and Treatment OncologyAdjuvant Ado-trastuzumab EmtansineMedicineAtempt TrialClinical Trials	2021	34
Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer Wendy Y. Chen, Karla V. Ballman, Ann H. Partridge, JAMA	2024	29
Abstract GS1-05: TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT) Sara M. Tolaney, Lorenzo Trippa, William T. Barry, Cancer Research Breast OncologyImmunotoxicologyImmunologyAdjuvant Trastuzumab EmtansineImmunotherapeutics	2020	26
Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer Romualdo Barroso‐Sousa, Inês Vaz-Luís, Antonio Di Meglio, The Oncologist	2021	16
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial Romualdo Barroso‐Sousa, Paolo Tarantino, Nabihah Tayob, npj Breast Cancer	2022	15
A randomized phase III, double-blinded, placebo-controlled trial of aspirin as adjuvant therapy for breast cancer (A011502): The Aspirin after Breast Cancer (ABC) Trial Wendy Y. Chen, Karla V. Ballman, Eric P. Winer, Journal of Clinical Oncology Breast OncologyOncologyCancer EpidemiologyCancer ManagementPharmacology	2022	14

Page 1